7-Hydroxymitragynine vs Mitragynine: Differences & Comparison | 7-Hydroxymitragynine.co

Table 01 · Mitragynine vs. 7-Hydroxymitragynine07 factors

Factor	Mitragynine	7-Hydroxymitragynine
Abundance in leaf	~66% of total alkaloids	<2% of total alkaloids
Relative mu-affinity	Baseline (1×)	~46× mitragynine, ~13× morphine
Receptor type	Partial mu-opioid agonist	Partial mu-opioid agonist (higher affinity)
Low-dose effects	Stimulating, focus-enhancing	Relaxing, analgesic
High-dose effects	Sedating, analgesic	Strongly sedating, analgesic
Metabolic relationship	Precursor (converted to 7-OH by CYP3A4)	Active metabolite of mitragynine
Self-administration in rats	Not reliably reinforcing	Reinforcing at morphine-comparable rates

Mitragynine is the precursor; 7-OH is the active metabolite

Mitragynine is converted to 7-hydroxymitragynine in vivo by the hepatic enzyme CYP3A4 (Kruegel 2019; Kamble 2020). When that conversion is blocked in animal models, the analgesic effect of ingested mitragynine largely disappears — even at doses that would normally produce strong antinociception. The clean interpretation: when you ingest leaf kratom, mitragynine itself is doing relatively little opioid work; most of the effect is coming from the 7-OH your liver produces from it.

This is the foundation of the “natural vs. concentrated” regulatory framing. A leaf kratom product hands the body a large reservoir of mitragynine and lets CYP3A4 meter out 7-OH at its own rate. A concentrated 7-OH product hands the body pre-formed 7-OH directly, removing the rate limit. The same alkaloid is being delivered to the same receptor — but the delivery profile is different.

Receptor profile

Both compounds are partial agonists at the mu-opioid receptor, but the affinities differ by roughly 46-fold in favour of 7-OH (Kruegel 2016). In rat drug-discrimination assays — a behavioural assessment of opioid-likeness — 7-OH fully substitutes for morphine while mitragynine does not (Obeng 2021). Mitragynine’s additional activity at adrenergic, serotonergic, and other monoaminergic targets contributes to the stimulating, focus-tilted effects users describe at low leaf doses; 7-OH is more selectively opioid in its profile.

Abuse liability is not symmetric either

Rats reliably self-administer 7-OH at rates comparable to morphine but do not reliably self-administer mitragynine (Hemby 2019). This asymmetry mirrors the receptor data: the precursor is largely inert as a reinforcer, the active metabolite is not. The clinical implication is that physical dependence on a 7-OH-concentrated product is expected to develop on a faster timeline than dependence on the same nominal alkaloid total delivered as leaf mitragynine. Timeline and management on the withdrawal page.